Squarepoint’s Medifast MED Stock Holding History

Squarepoint’s Portfolio MED Stock Details MED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-10,000	Closed	-$672K	–	4354
2023 Q4	$672K	Buy	+10,000	New	+$697K	﹤0.01%	2802

Other funds holding MED

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Squarepoint's MED Position: Q3 2024 in Review

Squarepoint sold out of Medifast (MED) in Q3 2024, closing a stake of 23,976 shares — an estimated $523K sold.

Squarepoint first reported a position in MED in Q4 2016 and held it in 23 quarters. The position peaked at $9.51M in Q1 2019. 140 funds tracked by Wall St. Rank hold MED as of Q3 2024.

Squarepoint reported no remaining Medifast position as of Q3 2024 after selling out during the quarter.
Squarepoint sold 23,976 Medifast shares in Q3 2024, an estimated $523K.
Squarepoint first reported a position in Medifast in Q4 2016 and held it in 23 quarters.
Squarepoint's Medifast position peaked at $9.51M in Q1 2019.
140 funds tracked by Wall St. Rank held Medifast as of Q3 2024.

Based on Squarepoint's 13F filing for Q3 2024, filed 14 Nov 2024.